Hypophosphatasia
Conditions
Keywords
Hypophosphatasia, HPP, Asfotase alfa, Strensiq
Brief summary
The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).
Detailed description
The administration of biological drugs to patients, especially for chronic conditions, carries a risk of eliciting anti-drug antibodies. Neutralizing antibodies can neutralize the clinical benefit of the agent. In postmarketing safety surveillance, some patients treated with asfotase alfa demonstrated an initial response, but subsequently recurrence and progression of disease. Consequently, the FDA requested a study to assess a potential serious risk of immune-mediated loss of effectiveness.
Interventions
DRUGmethotrexate
Methotrexate will be administered SC or orally weekly for 104 weeks.
DRUGrituximab
Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
DRUGbortezomib
Bortezomib will be administered via IV bolus or SC, as needed.
DRUGIVIg
IVIg will be administered via IV monthly through initial 74 weeks.
DRUGFolic Acid
Folic acid will be given orally as long as methotrexate is being dosed.
Sponsors
Alexion Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline. * Presence of ADAs, with or without NAbs, irrespective of their titers. * Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present. * Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance as described in Section 10.5. * Participant, or participant's legal guardian, is capable of signing informed consent or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol.
Exclusion criteria
* Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 \[HIV 1, HIV 2\] antibody) or hepatitis B or C viral infection. * Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening. * Inability of the participant, or the participant's legal guardian, to provide informed consent. * Pregnant, breastfeeding, or intending to conceive during the course of the study. * Inability to travel to the clinic for specified visits during the Treatment Period caused by disease per se or logistics (does not apply to external travel restrictions). * The participant is at risk of reactivation or has an active significant viral infection such as hepatitis B, cytomegalovirus, herpes simplex, human polyomavirus (also known as John Cunningham \[JC\] virus), parvovirus, or Epstein Barr virus. * The participant is at risk of reactivation of tuberculosis or has regular contact (eg, in the household) with individuals who are being actively treated for tuberculosis. * The participant has had or is required to have any live vaccination within 1 month prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Who Achieve Immunosuppressive Therapy (IST) Complete Response at Week 100 | Week 100 |
Secondary
| Measure | Time frame |
|---|---|
| ADA and NAb Titer Levels | Baseline Through Week 100 |
| Serum Concentration of Asofatase Alfa (Measured as Enzyme Activity) | Baseline Through Week 100 |
| Number Participants with Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) | Baseline Through Week 100 |
| Plasma Concentration of Inorganic Pyrophosphates (PPi) | Baseline Through Week 100 |
| Number of Participants with Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events | Baseline Through Week 104 |
| Plasma Concentration of Pyridoxal-5ˈ-Phosphate (PLP) | Baseline Through Week 100 |
Outcome results
None listed